Famed boot manufacturer Dr Martens has projected a significant financial setback due to US tariffs. The company, known for its iconic footwear, has shifted its production hub to Vietnam, which is facing increased import duties as a result of the trade tensions sparked by US President Donald Trump.
Dr Martens anticipates a multimillion-pound impact on its profits this year, primarily due to the higher tariffs on goods imported from Vietnam. The company has strategically transitioned its supply chain away from China, a former major production base, to mitigate the impact of US tariffs.
Despite the tariff challenges, Dr Martens remains optimistic about meeting its full-year profit forecasts, ranging between £53 million to £60 million in underlying pre-tax profits. However, this projection does not account for the expected tariff-related losses.
Following the announcement, Dr Martens’ stock price experienced a sharp decline of over 10% during early trading. The company, famous for its distinctive yellow-stitched boots, revealed plans to counterbalance the tariff expenses starting from the upcoming year.
Dr Martens aims to completely offset the increased tariffs beyond 2026/27 through stringent cost management, adaptable product sourcing, and targeted adjustments to its pricing strategy in the USA. In its recent financial update, the company disclosed a reduction in losses to £11 million for the first half of the fiscal year, with a 0.8% increase in sales.
Ije Nwokorie, the CEO of Dr Martens, highlighted the brand’s resilience, citing a 33% surge in shoe volumes and the successful launch of new products. Despite the current economic uncertainties and consumer caution, the company remains confident in its strategies for the upcoming year.
Investment director Russ Mould acknowledged Dr Martens’ progress in aligning the business towards profitability. While the company is in the early stages of its recovery journey, positive signs, such as improved product sales and narrowed losses, indicate a potential turnaround. However, market response to the half-year results has been lukewarm, with early trading reflecting investor disappointment.